Humacyte plans supplemental BLA for atev dialysis access
Humacyte says it plans to file a supplemental BLA with the FDA for atev in dialysis access in November 2026, seeking a second approved indication backed by three phase 3 studies.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Humacyte plans ATEV supplemental BLA filing for dialysis access
Humacyte says it plans a supplemental BLA filing for ATEV in dialysis access following FDA discussions.